OneFlorida+ネットワークにおける外部暴露因子と有害な心不全のアウトカム:遡及的なコホート研究
Wenxi Huang1, Stephen E Kimmel2, Mustafa Ahmed3
1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1889 Museum Road, DSIT 6004, Gainesville, FL, 32606, United States, 1 3522736533.
JMIR formative research
|August 25, 2025
まとめ
5月の高温は心不全 (HF) の再入院と死亡リスクを増加させる. この研究は,環境要因とHFの結果を関連付け,極端な熱に対するさらなる研究の必要性を強調しています.
科学分野:
- 環境衛生
- 心血管疾患の疫学
- 健康の社会的決定因子
背景:
- 心不全 (HF) の再入院率は,米国では地理的に変動しています.
- 健康の社会的決定因子 (SDoH) を含む外部被曝因子の有害なHF結果への影響は,まだ十分に理解されていません.
研究 の 目的:
- 外部暴露因子とHF再入院リスクと全原因死亡率との関連を調査する.
- 肝炎患者の治療結果に影響を与える環境的,社会的要因を特定するために,データ主導の方法論を活用する.
主な方法:
- OneFlorida+ネットワーク (2016-2022) の電子医療記録 (EHR) データを用いた遡及コホート研究
- 住所を基に1308の外部暴露因子 (SDoH) を患者の電子健康記録データと関連付けました.
- 変数選択のペナライズド回帰と,混合効果のロジスティック回帰による2段階のエクスポソーム全体の関連研究を使用した.
主要な成果:
- 分析には,HFのために入院した63, 940人の患者が含まれていた.
- 5月の最高気温上昇は,複合的なアウトカム (HF再入院と死亡率) のリスクの増加と有意に関連していました (aOR1. 04,95%CI1. 02-1. 06).
- 関連性は様々な人口統計的および社会経済的なサブグループで一貫したままでした.
結論:
- 高い5月の最高気温は,フロリダでのHF再入院と死亡率の増加と関連しています.
- 極端な熱がHFの結果に影響を与えるメカニズムを明らかにするためにさらなる研究が必要である.
関連する概念動画
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
01:26Heart Failure III: Clinical Manifestations
43
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
43
01:27Heart Failure I: Introduction
54
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
54
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505